Notably, DLL3, an inhibitory Notch ligand, has shown aberrant expression on the surface of small cell lung cancer (SCLC) and high-grade neuroendocrine tumors or small cell cancer outside the lung. This evidence concerns the gene DLL3 and small cell lung carcinoma.